Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Corbus Pharmaceuticals (CRBP) reported promising pre-clinical data for CRB-601, showing enhanced anti-tumor activity in combination with anti-PD1 therapy. The IND submission for CRB-601 is on track for the first half of 2023. The company holds $86.8 million in cash, sufficient to fund operations into Q1 2024. They also noted a reduced net loss of $9.4 million for Q1 2022, down from $16 million in Q1 2021, mainly due to lower clinical and manufacturing costs. Corbus aims to expand its immuno-oncology pipeline through strategic partnerships.
Corbus Pharmaceuticals (NASDAQ: CRBP) presented its first preclinical data for CRB-601 at the AACR Annual Meeting on April 8-13, 2022. CRB-601, a monoclonal antibody, targets αvb8 integrin to inhibit TGFb activation in tumors. The data revealed significant tumor growth inhibition in a colon cancer model, enhancing CD8-positive T cell infiltration. The company plans to submit an IND for CRB-601 in H1 2023, aiming to explore its anti-tumor potential in conjunction with existing immune therapies. The full poster and corporate presentation are available on their website.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET. The event will include virtual one-on-one meetings for registered investors. A live webcast will be available on the company’s website, with a replay accessible two hours post-event for 90 days. Corbus focuses on innovative immunology solutions targeting the immune system and cancer.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported its fourth quarter and year-end 2021 financial results, revealing a significant drop in revenue, totaling $0 for Q4 compared to approximately $658,000 in Q4 2020. The total revenue for 2021 was $882,000, down from $3.9 million in 2020. Operating expenses decreased by $11.5 million in Q4 and $69.9 million for the year, reaching approximately $10 million and $56.9 million, respectively. The company reported a net loss of $10.3 million for Q4 and $45.6 million for 2021. As of year's end, Corbus had $98.3 million in cash, expected to fund operations into Q1 2024.
Corbus Pharmaceuticals (NASDAQ: CRBP) has appointed Rachael Brake, Ph.D., as its new Chief Scientific Officer. Dr. Brake joins from Takeda Pharmaceuticals, bringing extensive experience in oncology drug development. She will advance Corbus' pipeline, focusing on TGFβ-targeting therapeutics and the endocannabinoid system. CEO Yuval Cohen emphasized her leadership as essential for the company's growth. Dr. Brake aims to enhance the impact of immuno-oncology therapies, especially with new acquisitions like CRB-601.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) provided updates and financial results for Q3 2021. The company is progressing its anti-integrin mAb program targeting solid tumors, with first patient dosing expected in H1 2023. Lenabasum's Phase 2 study data is anticipated in Q4 2021. Revenue decreased to approximately $97,000 from $1.23 million in 2020, while operating expenses fell to $14 million from $35.2 million due to reduced clinical costs. Corbus reported a net loss of $2.2 million, down significantly from $34.9 million year-over-year. The company holds $108 million in cash, funding operations into Q1 2024.
Corbus Pharmaceuticals Holdings, a leader in immunology, will have its CEO, Yuval Cohen, participate in a fireside chat at the Jefferies London Healthcare Conference from November 16-19, 2021. This event will be both virtual and in-person, giving attendees the opportunity to engage directly.
An audio webcast of the chat will be available on-demand starting November 18, at 8:00 AM GMT for registered attendees. The presentation aims to advance discussions on Corbus's innovative treatments targeting inflammation and fibrosis.
Corbus Pharmaceuticals Holdings (CRBP) reported its Q2 2021 results, noting that the primary endpoint in the Phase 3 DETERMINE study of lenabasum in dermatomyositis was not met, but activity was observed in other areas. The company plans to engage with the FDA to discuss the next steps. CRBP has $114 million in cash, projected to last into Q1 2024. Revenue from awards and licenses decreased to $137,000, while operating expenses fell to $16.8 million, resulting in a net loss of $17.1 million, an improvement from $38.1 million in Q2 2020.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the topline results of its Phase 3 DETERMINE study on lenabasum for treating dermatomyositis. The study failed to meet its primary endpoint of Total Improvement Score (TIS) at Week 28, with lenabasum achieving a mean TIS of 28.3 versus 26.7 in the control group (p = 0.1965). However, nominally significant improvements were noted in subtypes of the disease. Lenabasum was found to be safe and well-tolerated. The findings will be discussed with regulatory authorities as the company looks to explore next steps.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced today the expansion of its pipeline with two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, aimed at inhibiting TGFβ activation. These mAbs, licensed from UCSF and Panorama Research, target integrins associated with fibrotic diseases and certain cancers. Both are expected to enter Phase 1 testing in 2022. With $125 million in cash, Corbus plans to advance up to four programs into clinical development. The total upfront payment for the licensing deals is $2 million, with potential milestone payments reaching $206 million.